BIOKIN PHARMACEUTICAL(SH:688506) Sou Hu Cai Jing·2025-11-04 18:05Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is advancing its strategic initiatives by planning to issue H-shares and has received recognition for its innovative drug T-Bren, which targets HER2-positive gastric cancer patients [1][2][3] Group 1: Trading Information - As of November 4, 2025, Baili Tianheng's stock closed at 362.0 yuan, down 5.22%, with a turnover rate of 1.4% and a trading volume of 14,400 shares, amounting to a total transaction value of 530 million yuan [1] - On the same day, the net outflow of main funds was 17 million yuan, accounting for 3.21% of the total transaction value, while retail investors experienced a net outflow of 3.84% [1][3] Group 2: Company Announcements - The company held its fifth board meeting on November 4, 2025, where it unanimously approved the proposal for the global issuance of H-shares and listing on the Hong Kong Stock Exchange [1][3] - The board also approved the establishment of governance policies applicable post-H-share issuance, including diversity policies and shareholder communication procedures [1] Group 3: Product Development - The innovative drug T-Bren (HER2 ADC) has been included in the list of breakthrough therapy products by the National Medical Products Administration, targeting HER2-positive locally advanced or metastatic gastric cancer patients [2] - T-Bren is classified as a Class 1 biological product and has shown significant anti-tumor efficacy in clinical trials, with 14 ongoing trials covering various cancers [2]